H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on VYNE stock, giving a Buy rating on February 24.
Joseph Pantginis has given his Buy rating due to a combination of factors including VYNE Therapeutics’ strong financial position and promising clinical developments. The company ended 2024 with $61.5 million in cash, which is expected to support operations through the second half of 2026. This financial stability provides a solid foundation for ongoing and future projects.
Additionally, VYNE is making significant progress in its BETi portfolio, particularly with the repibresib gel for vitiligo and VYN202 for psoriasis. The upcoming Phase 2b results for repibresib in mid-2025 and Phase 1b data for VYN202 by the end of 2025 are anticipated to be key catalysts. These developments are seen as potential inflection points that could positively impact the company’s stock, reinforcing the Buy rating.
In another report released on February 24, LifeSci Capital also maintained a Buy rating on the stock with a $6.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYNE in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com